The molecular mechanisms underlying regulation of fluid production by secretory epithelia such as the choroid plexus are poorly understood.
Two CAMP-regulated inhibitors of protein phosphatase-1, inhibitor-l (I,) and a dopamineand CAMP-regulated phosphoprotein, M, = 32,000 , are enriched in the choroid plexus. We show here that these two phosphoproteins are colocalized in choroid plexus epithelial cells. We have developed a novel method for studying the phosphorylation state of DARPP-32 and I, in intact cells, using a phosphorylation state-specific monoclonal antibody. Several drugs and hormones that are known to alter fluid secretion and that increase CAMP levels (forskolin, isoproterenol, vasoactive intestinal peptide) or cGMP levels (atrial natriuretic peptide) or that may use additional second messenger pathways (5-HT), increase the phosphorylation of I, and DARPP-32 in rat choroid plexus. In contrast, dopamine does not alter CAMP and cGMP levels, or I, and DARPP-32 phosphorylation.
Our results indicate that DARPP-32, known to be regulated by dopamine in a number of tissues, can be phosphorylated in response to non-dopaminergic factors, including hormones acting through non-CAMP-dependent pathways.
Our results also raise the possibility that inhibition of phosphatase-1, as a result of I, and DARPP-32 phosphorylation, might be part of a final common pathway in the action of several factors that are known or thought to alter cerebrospinal fluid production.
Cerebrospinal fluid (CSF) is formed in and secreted from epithelial cells of choroid plexus (for review, see Cserr, 1971) . Although the physiological events underlying CSF production are beginning to be understood (see Johanson, 1989 , for recent review), the mechanisms that regulate this essential process re-main unclear. There is some evidence that CSF production is under neural and hormonal control and that some of the neurotransmitters and hormones involved act through the regulation of CAMP. For example, drugs that directly increase CAMP levels by activating adenylyl cyclase (i.e., cholera toxin or forskolin) have been reported to alter the rate of CSF production in choroid plexus (Epstein et al., 1977; Feldman et al., 1979) and the rate of aqueous humor production from the physiologically analogous ciliary process (Gregory et al., 198 1; Caprioli et al., 1984) . Several neurotransmitters and hormones, including norepinephrine and vasoactive intestinal peptide (VIP), also stimulate CAMP formation in choroid plexus and have been hypothesized to influence CSF production by this mechanism (Nathanson, 1979 (Nathanson, , 1980 Crook et al., 1984; Lindvall et al., 1985; Crook and Prusiner, 1986) . However, at present, the mechanisms by which CAMP might alter CSF formation are unknown. Neurotransmitters and hormones acting through CAMP are known to modulate cellular processes by the reversible phosphorylation ofproteins (Nestlerand Greengard, 1984) . One class of regulated phosphoproteins that has been postulated to play a role in the mediation of CAMP-associated hormone action is the protein phosphatase inhibitors, DARPP-32 (i.e., dopamineand CAMP-regulated phosphoprotein, A4, = 32,000) (Walaas et al., 1983a,b; Hemmings et al., 1984b; Walaas and Greengard, 1984) and inhibitor-l (I,) . Both proteins are phosphorylated by CAMPdependent protein kinase on a single threonyl residue and, in phosphorylated form, are potent inhibitors of protein phosphatase-I in vitro (Hemmings et al., 1984a) . DARPP-32 is abundant in brain neurons possessing the dopamine D,-receptor (e.g., medium-sized striatonigral neurons) (Ouimet et al., 1984; Hemmings and Greengard, 1986) and is phosphorylated in these cells in response to dopamine acting through CAMP-dependent protein kinase (Walaas et al., 1983a,b) . DARPP-32 is also found in high concentration in the choroid plexus Steardo and Nathanson, 1987) . However, prior reports suggest that dopamine is a poor activator of adenylyl cyclase in this tissue and there is no evidence for a distinct dopamine-sensitive adenylyl cyclase (Nathanson, 1980) . Because DARPP-32 phosphorylation has previously been shown to be regulated only by dopamine, this finding raises the question of whether DARPP-32 is uniquely a dopamine-regulated protein and whether DARPP-32 and homologous phosphoproteins might be involved in the action of other hormones and neurotransmitters. or rai I, (her sequence). CAMP-dependent protein kinase phosphorvlates a threonyl residue in a homologous region of both proteins; Thr3, in DARPP-32 (Hemmines et al.. 1984~) and Thr,. in I. (Cohen et al.. 1977) . The sequence of the synthetic peptide thatwas phosphorylated and used for immunization is indicated by a box. One letter amino acid codes are used: A, alanine; D, aspartate; E, glutamate; F, phenylalanine; I, isoleucine; L. leucine; M, methionine; P, proline; Q, glutamine; R, arginine; T, threonine; V, valine. The sequences are from bovine caudate DARPP-32 (Williams et al., 1986) and rabbit or rat skeletal muscle I, (Aitken et al., 1982; Elbrecht et al., 1990 ).
The present study investigates the possibility that other neurotransmitters and hormones known to regulate adenylyl cyclase activity in choroid plexus might regulate the phosphorylation state of DARPP-32 and I, in intact tissue. In addition, we examine the possibility that other choroid plexus-enriched hormone receptors known to activate CAMP-independent pathways may also participate in this regulation.
To study the state of phosphotylation of DARPP-32 and I,, we have used a phosphorylation state-selective monoclonal antibody raised against a phosphopeptide encompassing the DARPP-32 CAMP-dependent phosphotylation site. Given the almost identical sequence of DARPP-32 and I, in that region, the antibody also recognizes the phosphorylated form of I,.
Materials and Methods
Forskolin, atria1 natriuretic factor (ANF; rat sequence), and Pansorbin [Stuphylococcus aureus cells (SACS)] were obtained from Calbiochem (San Diego, CA). RPM1 1640 media, Nonidet P-40, vasoactive intestinal peptide (VIP, rat sequence), rabbit anti-mouse IgG, phenylmethylsulfonyl fluoride (PMSF), bovine serum albumin (BSA), isoproterenol HCI, serotonin (5-hydroxytryptamine HCI), 8-bromo-cyclic GMP (8-bromo-guanosine 3':5'cyclic-monophosphate), and dopamine (3-hydroxytyramine HCl) were purchased from Sigma Chemical Co. (St. Louis, MO). Acrylamide and nitrocellulose membrane were obtained from Bio-Rad Laboratories (Richmond, CA). 1251-labeled protein A and -yJ2P-ATP were from New England Nuclear (Cambridge, MA). SpragueDawley rats and pregnant CD-l mice were supplied by Charles River Laboratories (Wilmington, MA). Catalytic subunit of cyclic AMP-dependent protein kinase purified to homogeneity as described by Kaczmarek et al. (1980) was kindlv suoolied bv Dr. Anaus Naim and Atsuko Horiuchi. DARPP-32 was purihed from bovine caudate nucleus by a modification of the previously described method (Hemmings et al., 1984b; Williams et al., 1986) , including chromatography on DE-52 (Whatman), acid extraction, ammonium sulfate fractionation, and sequential chromatography on DEAE-Sephacel (LKB-Pharmacia), HAUltrogel (IBF), and Mono-Q (LKB-Pharmacia).
Monoclonal antibodies against DARPP-32 (C24-4D7, -5A, and -6A) ) were a gift of Dr. Hugh Hemmings. Monoclonal antibodies C24-5A and -6A but not 4D7 display a slight (approximately 1:3000) cross-reactivity with I,. The K, antibodv. selective for the kidnev (al) form of Na,K-ATPase; was kindly provided by Dr. Kathleen Sweadner (Sweadner and Gilkeson, 1985) . I,, purified from rabbit skeletal muscle (Nimmo and Cohen, 1978; Hemmings et al., 1984d) , and a highly specific rabbit antiserum (G 187) directed against I, were provided by Drs. Angus Naim and Hugh Hemmings.
Preparation of phosphopeptide antigens and phosphoproteins
The synthetic peptide chosen for immunization was a 1 O-residue peptide encompassing the cyclic AMP-dependent phosphorylation site<Thr,,) of bovine DARPP-32 corresnondina to residues 28-37 (Hemmines et al., 1984~; Williams et al., 1986) . The sequence of the peptide was NH,-Ile-Arg-Arg-Arg-Arg-Pro-Thr-Pro-Ala-Met-CONH1.
This sequence is identical to that surrounding the cyclic AMP-dependent phosphorylation site in rat and rabbit I, with the exception of the methionine residue in DARPP-32, which is a threonine in I, (Aitken et al., 1982; Elbrecht et al., 1990 ; see Fig. 1 ). Note also that the Met,, in bovine DARPP-32 is replaced by a leucine in the rat sequence (Ehrlich et al., 1990) . The peptide was synthesized by Dr. J. Elliot at the Yale University Protein and Nucleic Acid Chemistry Facility, by the solid-phase method (Hodges and Merrifield, 1975) using a model 430A Applied Biosystems Peptide Synthesizer, and was purified by preparative reverse-phase HPLC using two Vydac C,, columns (25 x 250 mm) in series. Purity was estimated to be >95% by analytical HPLC and amino acid analysis, and was verified by mass spectrometry (data not shown).
The synthetic peptide was phosphorylated in vitro by the catalytic subunit of cyclic AMP-dependent protein kinase. A typical reaction mixture contained 2 mM peptide, 5 mM y'*P-ATP (specific activity, 0.3 Ci/mol), 10 &ml catalytic subunit, 50 mM HEPES, pH 7.4, 10 rnM magnesium acetate, and 1 mM EGTA in a volume of 6 ml. Incubation was carried out for 18 hr at 30°C and stopped by addition of 3 ml of glacial acetic acid. Dowex AG I-XB (2 ml) was added, and the mixture was stirred at 4°C for 1 hr and poured onto a small column. The flowthrough and a 4 ml wash were pooled, lyophylized, and redissolved in H,O. The phosphorylated form of the peptide was separated from the remaining unphosphorylated peptide (< 5%) by HPLC on a preparative Vydac C,, reverse-phase column. Elution was performed with an increasing linear gradient of solvent B (70% CH,CN, 0.085% trifluoroacetic acid in H,O) in solvent A (0.1% trifluoroacetic acid in H,O) as follows: O-3 min, 0% B; 3-8 min, O-l 8% B; 8-10 min, 18-22% B. The purified phosphopeptide was coupled to Limuh hemocyanin (Sigma), which was shown to be devoid of contaminating phosphatase activity. Coupling was carried out using 0.15% glutaraldehyde for 120 min at 4°C in 2.6 ml of 68 mM sodium phosphate, pH 7.4. The reaction was stopped by the addition of 150 ~1 of sodium borohydride (25 mg/ml). The coupled peptide was dialyzed against two times 4 liters of a buffer containing 10 mM sodium phosphate, pH 7.4, and 150 mM NaCl.
Preparative phosphorylation of DARPP-32 or I, was carried out in conditions similar to those described above for the peptide using lowspecific-activity y'*P-ATP (0.1 Ci/mmol). The concentration of protein substrate was 10-20 PM, and the amount of catalytic subunit was 5 pg in a final volume of 100 ~1. Aliquots of the reaction mix were heated to 100°C for 1 min in a boiling water bath to stop the reaction and used for calculating the stoichiometry of phosphorylation. y32P-phospho-DARPP-32 was separated from remaining nucleotide di-and triphosphate by anion-exchange chromatography as described for the peptides. Control dephospho-DARPP-32 or dephospho-I, were treated the same way except that the protein kinase was omitted from the reaction mixture.
Iodination of phospho-DARPP-32 (2.2 nmol) was carried out for 15 min at room temperature with an Iodo-Bead (Pierce) using 2.5 mCi of lZ51-Nal in 2 15 ~1 of 90 mM sodium phosphate buffer, pH 7.4. Iodinated phospho-DARPP-32 was separated from free iodine by chromatography on a 1 x I2 cm column of Sephadex G-25 equilibrated in a buffer containing 100 mM sodium phosphate, pH 7.4, 0.25% (w/v) bovine serum albumin, and 0.1% (w/v) sodium dodecyl sulfate.
Production of monoclonal antibodies against phospho-DARPP-32 peptide Monoclonal antibodies were prepared against the phosphorylated peptide using the method of Kohler and Milstein (I 975) . The phosphopeptide conjugated to Limulus hemocyanin was used to immunize Balb/c mice. Spleen cells from mice whose serum was reactive with phospho-DARPP-32 were fused with SP 2/O mouse mveloma cells. Screenine of mouse sera and fusion supematants was first carried out using a modiied ELISA. Nunc II plates (96 well, Nunc, Sweden) were coated overnight with aliquots (1 &well) of the 10 amino acid phosphorylated peptide (conjugated to BSA) that had been used for immunization of mice. After blocking with 1% BSA in PBS, supematants from fusion hybrids (100 ~1) were added and incubated for 30 min at 37°C. The plates were washed three times with PBS containing 1% BSA and 0.1% Tween 80. Goat From approximately 2000 clones initially screened using this procedure, about 500 showed positive color reactions with the phosphorylated DARPP-32 peptide and were further tested with regard to their specificity for the phospho-versus dephospho-form of the native protein.
The protocol for these experiments was essentially the same as that used for the primary screening except that plates were coated with aliquots of dephosphorylated or phosphorylated DARPP-32 purified and prepared as described above. Nearly 50% of these clones reacted preferentially with the phosphorylated DARPP-32, and 27 of these were selected for further use. The antibody produced by one of these clones (mAb 23) was shown to react strongly with the phospho-form but not the dephospho-form of DARPP-32 and was further assessed by immunoprecipitation of r)*P-phospho-DARPP-32, as described previously and by dot-immunobinding assay. These cells were injected (intraperitoneally) into Balb/c mice primed with pristane (0.5 ml/mouse). Ascites was collected from these mice for use in the present experiments and stored at -70°C.
Immunoprecipitation of phospho-DARPP-32
Microcentrifuge tubes containing 1251-labeled phospho-DARPP-32 ( 10,000 cpm/tube), 1: 10 dilution of ascites, and various concentrations of an unlabeled competing antigen (dephospho-DARPP-32, phospho-DARPP-32, dephospho-I,, phospho-I,) were incubated for 2 h at 4°C in 0.1 ml of NETF buffer, of the following composition 100 mM NaCl, 5 rnM EDTA, 50 mM Tris HCl, pH 7.5, 50 mM NaF, 1% NP-40, 100 mM phenylmethylsulfonyl fluoride (PMSF), and 1 mg/ml BSA. A 25 ~1 aliquot of rabbit anti-mouse IgG was added to each tube, and these samples were incubated for an additional hour at 4°C. A solution of StaQhylcoccus aureus cells (SACS) bearing protein A (3.1 mg protein/ ml) that had been washed and suspended in NETF buffer containing 25'mg/ml BSA was then added (56 PI/tube), and the tubes were incuz bated for a 30 min period at 4°C. The tubes were centrifuged in a Beckman J-6M centrifuge at 1000 x g for 15 min. The resulting SAC pellet was washed two times with 0.1 ml of NETF, and its radioactivity was measured using a Beckman 5500 gamma counter. of catalytic subunit used was decreased by a factor of 1000 in order to reduce the rate of protein phosphorylation and facilitate measurement of time-dependent increases in phosphate incorporation. Parallel phosphorylation reactions were carried out in two tubes, one that received 1 mM unlabeled ATP and another that received 1 mM -r32P-ATP (2 mCi/ml). Both tubes were incubated for 60 min. At 2.5, 5, 7.5, 10, 15, 30, 45, and 60 min, a 10 ~1 aliquot of the phosphorylation mix was removed from each tube, added to a 50 ~1 aliquot of sample buffer, and boiled for 3 min at 95°C. Proteins were separated by SDS-PAGE on a 12% acrylamide gel.
Immunoblotting
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose membranes was carried out according to Towbin et al. (1979) . Dot blots were prepared by spotting 1 ~1 of phospho-or dephospho-DARPP-32 at concentrations ranging from I to 100 &ml on nitrocellulose strips. Proteins were fixed by a 10 min incubation in 25% isopropanol and 10% glacial acetic acid. Immunolabeling was performed as described for DARPP-32 and I, . Labeling of the antibodies was achieved by incubating the membranes sequentially in affinity-purified rabbit anti-mouse IgG (1:500, Cappell, when a mouse primary antibody was used) and 'Wiodo-protein A as described previously .
Preparation and treatment of striatal reaggregate cultures
Striatal reaggregate cultures were prepared from embryonic day 14 CD-1 mouse embryos as described previously (Hemmendinger et al., 198 1) with a few modifications (Girault et al., 1988) . Three-week-old reaggregate cultures were incubated for 1 hr in modified Krebs' buffer and further incubated in the presence or absence of forskolin as described previously (Girault et al., 1988) . Incubations were stopped by aspiration of the buffer and immersing the tubes containing the aggregates in liquid nitrogen. Cells were stored at -70°C until analysis. Reaggregates were homogenized by sonication in 1% boiling SDS and placed for an additional 10 min in a protein boiling water bath. Equal amounts of protein (150-350 pg) in sample buffer were subjected to SDS-PAGE and immunoblotting as described above.
Pharmacological treatment of rat choroid plexus
Rats were decapitated, and choroid plexus was dissected from the lateral cerebral ventricles. Choroid plexus from five rats per treatment condition were incubated in 25 ml Ehrlenmeyer flasks containing 20 ml of oxygenated RPM1 1640 medium in a shaking water bath (30°C). After a 45 min preincubation period, medium was replaced with fresh normal RPM1 1640 or medium containing drug, and the tissue was incubated for an additional 5-45 min. After drug treatment. choroid plexuses were rapidly transferred to glass tubes using a Pasteur pipette and homogenized in 5 vol of cold 5 mM zinc acetate. The tissue was acid extracted and proteins separated by SDS-PAGE as described above (In vitro phosphorylation of proteins in acid extracts). In addition, a 0.5 ml aliquot of the incubation medium and a 0.1 ml aliquot of the zinc acetate homogenate were retained from control and drug-treated tissue, acidified with an equal volume of 0.2 N HCl, and used for cyclic AMP determinations using the method of Brooker et al. (1976) .
In vitro phosphorylation of proteins in acid extracts
Male Sprague-Dawley rats weighing 250-300 gm were killed by decapitation. The brains were placed on an ice-cold glass plate, and either corpus striatum or choroid plexus from lateral ventricles was dissected.
Tissue was homogenized in 10 vol of cold 5 mM zinc acetate and centrifuged at 3000 x g for 10 min, and the pellet was resuspended in 10 vol of 10 mM citric acid containing 0.1% Nonidet P-40. This acid extract was neutralized to pH 7.0 by addition of 0.1 vol of0.5 M Na,HPO, and boiled at 95°C for 1 min. This neutralized extract was centrifuged at 10,000 x g for 10 min, and the supematant was used for in vitro phosphorylation. Phosphorylation was carried out in a buffer containing 50 mM HEPES, pH 7.4, 10 mM magnesium acetate, 1 mr+r EGTA, 20 PM ATP, and 1 &ml catalytic subunit ofcyclic AMP-dependent protein kinase. The tubes were incubated in a shaking water bath at 30°C for 30 min. The incubation was terminated by the addition of an equal volume of "sample buffer" containing 50 mM Tris HCl, pH 6.8, 10% glycerol, 2% sodium dodecyl sulfate (SDS), 10% 2-mercaptoethanol, and 0.01% bromophenol blue. Samples were heated at 95°C for 3 min and subjected to klectrophoresis on 12% acrylamide gels (Laemmli, 1970) .
Immunohistochemical identification and localization of DARPP-32, I,, and Na,K-ATPase in rat choroid plexus Intact tissue. Intact lateral and fourth ventricular choroid plexuses from 8-week-old male Sprague+Dawley rats were dissected in Dulbecco's modified Eagle's medium (DMEM) and meticulously cleaned of any adhering meninges or brain under a high-power dissecting scope. Samples of lateral and fourth ventricular choroid were cut into 2-4 mm pieces, fixed for 1 hr in 1.5% or 2% paraformaldehyde, washed twice for 5 min in phosphate-buffered normal saline (PBS), and then stored at 0°C. Prior to immunostainina, the pieces of choroid were transferred to albumin-coated slides and ayr dried.
Epithelialand vascular cellfractions. Choroid epithelium was isolated and separated from choroid stroma as described previously (Nathanson, In vitro phosphorylation of puriJied DARPP-32 and inhibitor-1
The time course of phosphorylation of DARPP-32 and I, by CAMP-1980; Nathanson and Chun, 1989) . Briefly, pooled choroid plexuses dependent protein kinase as measured by immunoblotting with mAb (above) were further washed (3 x 10 min) in 10 ml of DMEM by gently 23 was compared with the time course of phosphate incorporation from tumbling (90 rpm) in a Rotovapor apparatus (in a 100 ml spherical -$*P-ATP. Preparations of DARPP-32 and I, (10-20 PM) were phosflask), which allowed suspended cells to be separated and removed from phorylated in vitro as described above. In addition, the concentration intact tissue. Subsequently, tissue was tumbled in calcium-free artificial purified DARPP-32 were spotted on nitrocellulose strips and detected by incubation with various dilutions of mAb 23 (triangles, 1:50,000; circles, 1:5000). Antibody binding was determined by sequential incubation with rabbit anti-mouse IgG (1:500 dilution) and 12SI-iodo-protein A (1: 1000 dilution) and was quantitated by gamma radiation counting. Each point represents the mean of triplicate determinations.
CSF (Nathanson, 1980) containing 0.05% trypsin (Sigma) and 15 PM EDTA. Every 15 min for 4 hr, choroid plexuses were gently triturated and allowed to settle, and supematant fractions containing suspended cells were removed from intact tissue; in this manner, a large peak of highly enriched epithelial cells was obtained (usually fractions 5-lo), prior to the onset of dissociation of the choroid plexus stroma (usually fractions 11-I 5). Cells from pooled fractions 5-10 were filtered through 150 pm Nitex mesh to remove large cell aggregates, centrifuged and washed at low speed with PBS, and then fixed in 1.5% or 2% paraformaldehyde for 1 hr. Following two washes with PBS, approximately l-5 x 1 O4 cells were air dried on albumin-coated slides. The remaining, largely deepithelialized and fragmented choroid plexus present in the original dissociating flask were washed with PBS and fixed as above, and then aliquots were air dried on albumin-coated slides.
For pharmacological studies of cyclic nucleotide accumulation in isolated choroid epithelium, cells, isolated as above, were preincubated for 60 min at 34°C in DMEM containing 40 mM HEPES under 95% 0,. 5% CO,. Aliquots of 1 x lo5 cells were then transferred to tubes co;: taining 0.2 ml of artificial CSF (Nathanson, 1980) supplemented with 0.1% bovine serum albumin and 2.5 mM ascorbic acid. Either dopamine (100 PM) or ANF (1 PM) was added, and cells were incubated for 3 min, following which an equal volume of I50 mM sodium acetate was added and the tubes heated to 90°C for 3 min. Tubes were then centrifuged, and CAMP and cGMP levels were determined in the supematant by radioimmunoassay (Du Pont).
Immunostaining. Air-dried slides of whole choroid or choroid cell fractions were washed three times with PBS and once (for 10 min) with 4% goat serum, and incubated overnight at 4°C with rabbit polyclonal antibody (K2, I : 150) to the a-form of Na,K-ATPase, with mouse monoclonal antibody (1:300) to DARPP-32, or with rabbit polyclonal antiserum (G 187, 1:50-1:150) to I, diluted in 0.1% Triton X-100 and 4% goat serum in PBS. Following five washes with PBS, slides were incubated for 1 hr at room temperature with the appropriate fluorescein-or rhodamine-labeled goat secondary antibody [F(ab'), fragment] (Cappel Labs, I:100 dilution), washed five times with PBS, mounted in 67% glycerol containing 0.67% propyl gallate, and viewed by epifluorescence with an inverted microscope.
Log hAI Miscellaneous methods. Autoradiography was performed using Kodak XAR-5 film at room temperature or at -70°C with Du Pont Quanta II intensifying screens. Amounts of '251-iodo-protein A bound to the antigen on nitrocellulose filters, or of y32P-phosphate incorporated into proteins, were determined by excising the radioactive bands using autoradiograms as guides. 'Z51-iodine was then measured in a gamma counter, and y3*P-phosphate was quantified by scintillation spectrometry or by determination of Cerenkov radiation. Data were analyzed by ANOVA (for post hoc comparisons), with significance defined as p < 0.05. Protein concentrations were measured by the bicinchoninic acid method (Smith et al., 1985) or by the method of Lowry et al. (195 l) , using bovine serum albumin as a standard.
Results
In vitro characterization of a monoclonal antibody speciJic for DARPP-32 phosphorylated by CAMP-dependent protein kinase. In dot-immunobinding assays, mAb 23 reacted with phospho-DARPP-32, but not dephospho-DARPP-32 (Fig. 2) . The ability of this antibody to distinguish between phospho-and dephospho-forms of DARPP-32 was demonstrated further by competitive immunoprecipitation experiments in which precipitation of holo-1251-iodo-phospho-DARPP-32 was inhibited effectively by unlabeled phosphorylated DARPP-32, but not dephosphorylated DARPP-32 (Fig. 3) . Because of the similar primary sequences surrounding the CAMP-dependent phosphorylation sites of DARPP-32 and I,, the precipitation of radiolabeled substrate also was inhibited competitively by phosphorylated I, in a concentration-dependent manner (Fig. 3) . Aliquots of these reaction mixtures were withdrawn at various times and subjected to SDS-PAGE. Gels containing samples phosphorylated with radiolabeled phosphate were directly autoradiographed. Proteins phosphorylated in parallel experiments using cold ATP were transferred to nitrocellulose membranes and immunoblotted using mAb 23, rabbit anti-mouse IgG (I:500 dilution), and 1251-iodo-protein A ( 1: 1000 dilution). Radioactivity was counted in excised segments of gel (rs2phosphate) or nitrocellulose membranes (l*%odine) in order to quantitate phosphate content of proteins at each time point.
Dephospho-I,, like dephospho-DARPP-32, had no significant effect on the immunoprecipitation of lZSI-iodo-phospho-DARPP-32 by mAb 23 (Fig. 3) . The correlation between DARPP-32 phosphorylation and the detection of the protein by mAb 23 was examined by following the time course of DARPP-32 phosphorylation in the presence of CAMP-dependent protein kinase (Fig. 4) . The y32P-phosphate content of DARPP-32 increased rapidly within the initial 15 min of exposure to the kinase, as did the immunoreactivity of the protein toward mAb 23. Under the same conditions, I, was phosphorylated at a slower rate than DARPP-32 as indicated both by phosphate content and immunoreactivity of the protein.
Further characterization of the phospho-DARPP-32 antibody using striatal extracts and striatal reaggregate cultures. The usefulness of mAb 23 for detection of phosphorylated DARPP-32 in brain and peripheral tissues first was assessed using striatum, a brain region in which DARPP-32 is highly enriched (Hemmings and ). An immunoreactive band with an apparent M, of -34,000 was revealed by this antibody in acid extracts of adult rat striatum that had been phosphorylated in vitro with catalytic subunit of CAMP-dependent protein kinase (Fig. 5, lane 4) , but not in extracts incubated in the absence of the kinase (Fig. 5, lane 3) . This protein band was identified as DARPP-32 using a mixture of C24-6A and -5A monoclonal antibodies (mAb 5,6, Fig. 5, lanes 1, 2) . A comparable protein band was revealed in SDS homogenates prepared from 3-week-old striatal aggregate cultures that had been incubated for 6 min in the presence of forskolin (50 MM), a drug known to stimulate CAMP formation (see Seamon and Daly, 1986) and thereby activate endogenous CAMP-dependent protein kinase. Forskolin treatment increased phospho-DARPP-32 immunoreactivity in striatal cells (Fig. 5, lane 6) , whereas no detectable immunoreactivity was present in homogenates from untreated striatal cultures (Fig. 5, lane 5) . Additional immunoreactive bands with apparent IV, -75,000 and -100,000 were observed. These immunoreactive bands were also found ; and by rhodamine optics, immunostained for Na,K-ATPase (C). Note presence and localization of DARPP-32 immunoreactivity in choroid plexus villae, which are covered with CSFin tissues from adult rat (data not shown). However, these protein bands were not affected by forskolin treatment, and were not recognized by other antibodies specific for DARPP-32 or I, (Fig. 5 , and data not shown; see also below).
Immunohistochemistty
of DARPP-32 and I, in rat choroid plexus. The increased formation of CAMP observed in choroid plexus in response to pharmacological treatment of this tissue occurs primarily in the epithelial cells (Nathanson, 1980) . In the present studies, we examined whether DARPP-32 and I, were localized to this cell type. Tissue slices of rat choroid plexus from both lateral and fourth ventricle showed bright immunoreactive staining for DARPP-32. Figure 6 shows an example of lateral ventricular choroid that consists of numerous epithelial-covered capillary loops (villae) arising from a veil-like ependymal membrane that floats within the ventricle. These can be visualized by phase contrast in Figure 6A , but are much more easily seen in Figure 6B , which shows that the bright immunoreactive staining for DARPP-32 is localized primarily to the thicker epithelial-covered loops. Other loops, below the plane of focus, appear fainter. Staining was brightest in epithelial cells, the nuclei of which were unstained (Fig. 6B) . The pattern of staining for the al (kidney) form of Na,K-ATPase, an enzyme known to be present in very high concentration in choroid plexus and other transporting epithelium (Milhorat, 1976; Sweadner and Gilkeson, 1985; Nathanson and Chun, 1989) , was nearly identical to that seen for DARPP-32 (Fig. 6C') .
Choroid plexus from the lateral and fourth ventricles was subjected to cell separation to produce two fractions: (1) a purified preparation of epithelial cells (Fig. 7C-F) , and (2) a largely deepithelialized vascular fraction consisting of collapsed capillaries, arterioles, and stroma (Fig. 7A,B) . The absence of staining of the latter fraction demonstrates the selective localization of DARPP-32 to choroidal epithelium. As shown in Figure 7A (phase), a few typical large, round epithelial cells remained attached to the vascular choroidal surface following cell isolation.
In Figure 7B , these, but not the remainder of the choroid, stain brightly for DARPP-32. Cells from the epithelial cell fraction (Fig. 7C,D) demonstrate bright immunoreactive staining both for Na,K-ATPase (Fig. 7C ) and DARPP-32 (Fig. 70) . Figure  7E (phase) shows another group of isolated epithelial cells, used as a staining control, in which nonimmune mouse serum was substituted for the mouse monoclonal DARPP-32 antibodies. No secondary antibody immunofluorescence was observed (Fig. 
70.
The immunohistochemical localization of I, is shown in Figure 8. Figure 8A shows by phase contrast a fragment of fourth ventricle choroid plexus, which, in one area (arrows), has been partially deepithelialized by treatment with trypsin, exposing capillaries underneath. Antiserum to I, results in bright staining of the epithelium (Fig. 8B) but not the deepithelialized area. Figure 8Cis a control section of isolated epithelial cells, in which nonimmune rabbit serum was substituted for the rabbit antiserum against I,. No immunofluorescence is observed. Figure Figure can be seen free above the piece. Figure 8E shows that antiserum to note that the DARPP-32 antibodies used for immunohisto I, immunostains the intact epithelium and free epithelial cells, tochemistry showed little (1:3000) cross-reactivity with I,. Likewith little or no localization to blood vessels. In Figure 8F , the wise, the G-187 antibody used for histochemistry of I, showed same piece of choroid has been colabeled for DARPP-32, showno cross-reactivity to DARPP-32 (see Fig. 9 ). In this slide, one ing a similar distribution of staining intensity. It is important of the capillaries shows some immunoreactivity to DARPP-32, and -34,000 only in forskolin-incubated tissue. The upper band was identified as DARPP-32 (lane 3) usina the selective DARPP-32 antibody C24-4D7, which do& not cross-react with I,. The lower band was identified as I, (lane 4), using a selective rabbit antiserum, G-l 87. Note that mAb 23 detected an additional band (LW~ -70,000) that was unaltered by forskolin treatment, similar to a band detected by this antibody in SDS-homogenized striatal cell aggregates (see Fig. 5 ).
although in most instances (e.g., Fig. 7B ) choroid vascular fractions did not stain with DARPP-32 immunoreactivity.
Phosphorylation of DARPP-32 and I, in rat choroid plexus.
Two bands of M, -29,000 and -34,000 were detected by mAb 23 in acid extracts from whole rat choroid plexus that had been incubated in vitro with forskolin (10 PM) but not in extracts prepared from untreated choroid plexus (Fig. 9, lanes 1, 2) . These two bands were identified as DARPP-32 (M, -34,000) and I, (MT -29,000) using either a monoclonal antibody (C24-4D7) that reacts specifically with DARPP-32 (Fig. 9, lane 3) or a rabbit antiserum (G-187) that detects specifically I, (Fig. 9 , lane 4). Forskolin markedly stimulated CAMP accumulation in extirpated choroid plexus (Fig. 10) . The forskolin-stimulated phosphorylation (Figs. 9, 10) appeared within 5 min but was undetectable 3W5 min after drug treatment (data not shown). A protein band of apparent M, -70,000 also was revealed by mAb 23 in acid extracts of choroid plexus (Fig. 9, lanes 1, 2) . Like the cross-reactive band of comparable molecular weight found in striatum, this band was not apparently regulated by forskolin (Fig. 9, lanes 1,2) , nor was it detected by other DARPP-32-and I,-selective antibodies (Fig. 9, lanes 3, 4, respectively) . Isoproterenol, a p-adrenergic agonist (10 PM), and VIP (1 PM) stimulated phosphorylation of I, and DARPP-32 (Fig. 10) . These drugs also elevated CAMP levels in choroid plexus, an observation that is consistent with the previously reported effects of these treatments on CAMP accumulation in bovine, cat, and rabbit choroid plexus (see Nathanson, 1979 Nathanson, , 1980 Crook et al., 1984; Crook and Prusiner, 1986) . Propranolol(l0 PM), a p-adrenergic antagonist, blocked both the rise in CAMP levels and the increased phosphorylation of DARPP-32 and I, produced by isoproterenol. Dopamine (10 PM) failed to elevate CAMP levels significantly in choroid plexus and produced no detectable changes in DARPP-32 or I, phosphorylation in this tissue. Incubation of choroid plexus with 5-HT (10 PM) increased the phosphorylation state of both DARPP-32 and I,. 5-HT also produced a small, but statistically insignificant, rise in CAMP levels in choroid plexus (Fig. 10) . DARPP-32 and I, are phosphoxylated in vitro by cGMPdependent protein kinase on the same threonyl residue phosphorylated by CAMP-dependent protein kinase (Hemmings et al., 1984b) . Choroid plexus epithelial cells express relatively high concentrations of cGMP and cGMP-dependent protein kinase (Cumming et al., 198 1) . Since ANF has been shown to stimulate cGMP formation in these cells (Steardo and Nathanson, 1987) , we examined whether ANF treatment might also be involved in regulating protein phosphorylation in extirpated choroid plexus. ANF (1 PM) increased the immunoreactivity of DARPP-32 and I, to mAb 23 (Figs. 10, 1 l) , as did incubation of intact choroid plexus with the cGMP analog I-bromo-cyclic GMP (4 mM) (Fig. 11) . In whole choroid plexus, a very slight increase in CAMP level was also observed in the presence of ANF (Fig. 10) . However, in experiments using isolated epithelial cells, ANF (1 PM) caused no increase in CAMP content in contrast to a substantial increase in cGMP content (Fig. 12 ). strate (Nairn et al., 1982) , a cGMP-regulated phosphoprotein that is enriched in cerebellar Purkinje cells (Detre et al., 1984) . The present study demonstrates that this strategy is generally applicable and provides an excellent tool for studying the regulation of phosphorylation of specific proteins under physiological conditions. Phospho-specific antibodies have now been generated against the CAMP-dependent protein kinase phosphorylation site (site 1) and the Ca2+/calmodulin-dependent protein kinase II sites (sites 2 and 3) in synapsin I, a nerve terminalassociated protein (Czernik et al., 1989 (Czernik et al., , 1991 . In the present study, the recognition of phospho-DARPP-32 and phospho-I, by the same antibody is not surprising due to the high degree of sequence homology existing between the CAMP-dependent phosphorylation sites of the two proteins Williams et al., 1986) . mAb 23 cross-reacted with two unidentified protein bands of higher molecular weight present in brain and in choroid plexus in a manner that was independent of CAMP stimulation. These cross-reacting species did not appear to be otherwise related to DARPP-32 and/or I, since they were not detected using antibodies specific for these proteins. This cross-reactivity may preclude immunocytochemical applications of mAb 23. However, when combined with electrophoretic protein separation techniques, this antibody proved to be a valuable tool in studying the regulation of DARPP-32 and I, phosphorylation in choroid plexus. Choroid plexus contains high concentrations of DARPP-32 ) and of I, (H. C. Hemmings, J. A. Girault, A. C. Naim, G. Bertuzzi, and P. Greengard, unpublished observations) . The present study demonstrates that DARPP-32 and I, are colocalized in epithelial cells, which also contain high levels of Na,K-ATPase. Similarly, striatonigral neurons that contain high levels of DARPP-32 (Ouimet et al., 1984; Walaas et al., 1984; Hemmings and Greengard, 1986) also contain relatively high levels of I, (Naim et al., 1988; Gustafson et al., 199 l) , while many other brain regions and tissues contain high levels of I, but no DARPP-32 (Gustafson et al., 199 1; see also Huang and Glinsman, 1976) . This suggests that, in addition to their common property of being CAMP-regulated inhibitors of phosphatase-1 (for a review, see Shenolikar and Naim, 1991), DARPP-32 and I, may have distinct properties that would require their coexpression at high levels in specific cell types. Isoproterenol and VIP increased levels of phospho-DARPP-32 and phospho-I, and also elevated CAMP levels in intact choroid plexus. Isoproterenol is known to increase CAMP formation by stimulating a @,-adrenergic-sensitive adenylyl cyclase of high specific activity present in the choroid plexus (Nathanson, 1979 (Nathanson, , 1980 see also Rudman, 1977) . Consistent with the observed localization of DARPP-32 and inhibitor-1 to choroid epithelial cells (Figs. 6-8 ), &adrenergic-sensitive adenylyl cyclase also is highly enriched in the secretory epithelium. VIP also is known to increase CAMP levels in choroid plexus and in choroid plexus epithelial cells (Crook et al., 1984; Lindvall et al., 1985; Crook and Prusiner, 1986) as well as in the epithelium of the related ciliary process (Mittag et al., 1985) . The above data indicate an association between hormonal activation of adenylyl cyclase in choroid plexus (particularly in choroid epithelium) and hormonal stimulation of phosphorylation of DARPP-32 and I,. This association between CAMP and phosphorylation state is further supported by the observed stimulation of phosphorylation by forskolin, a compound known to activate adenylyl cyclase directly in a variety of tissues (Seamon and Daly, 1986) . Collectively, these observations suggest that several neurotransmitters and hormones that stimulate adenylyl cyclase can stimulate CAMP-dependent phosphorylation of DARPP-32.
Dopamine did not increase CAMP levels in choroid plexus and also failed to increase the phosphorylation of DARPP-32 and I,: These observations are consistent with the results of several studies that have failed to demonstrate a dopaminesensitive adenylate cyclase activity in choroid plexus (Rudman et al., 1977; Nathanson, 1979 Nathanson, , 1980 and with several recent reports that failed to demonstrate specific binding to dopamine D, receptors in rat choroid plexus (Nicklaus et al., 1986; Yamamoto and Kebabian, 1989 ). This finding is of particular significance since DARPP-32 is highly enriched in brain regions possessing high levels of D, receptors (Ouimet et al., 1984) . The present study demonstrates the expression of DARPP-32 in cells lacking dopamine-sensitive adenylyl cyclase. These results suggest that although DARPP-32 is abundant in dopaminoceptive cells, the expression of this phosphoprotein alone cannot be accepted as a reliable marker for dopamine receptors. The present study also provides evidence that CAMP-independent effector systems may regulate DARPP-32 and I, phosphorylation in choroid plexus. Thus, ANF caused a pronounced stimulation ofthe phosphorylation of DARPP-32 and I,. It also caused a very small elevation of CAMP content in the intact choroid, but no CAMP elevation in isolated epithelial cells, indicating that the slight increase occurred in some nonepithelial cell location. This latter observation is consistent with prior experiments with choroid plexus membrane preparations showing that ANF fails to activate adenylyl cyclase (Steardo and Nathanson, 1987) . On the other hand, ANF (but not dopamine) elevated choroid epithelial cell cGMP levels, and it has previously been demonstrated that choroid plexus membranes contain an ANF-activated guanylyl cyclase of high specific activity enriched in the epithelium (Steardo and Nathanson, 1987) . DARPP-32 and I, are phosphorylated in vitro by CAMP-dependent protein kinase and cGMP-dependent protein kinase on the same threonyl residue (Hemmings et al., 1984d) . Because cGMP-dependent protein kinase is known to be enriched in choroid epithelial cells (Cumming et al., 1981) our results strongly suggest that ANF increases DARPP-32 and I, phosphorylation in choroid plexus through elevation of cGMP levels and consequent activation of cGMP-dependent protein kinase. Consistent with this hypothesis was the observation, in the present experiments, that 8-bromo-cGMP, an analog of cGMP able to penetrate cells, enhanced DARPP-32 and I, phosphorylation.
In the present experiments, 5-HT also induced substantial phosphorylation of DARPP-32 and I, in choroid plexus, but only a small increase in CAMP (as reported previously; see Rudman et al,, 1977; Crook et al., 1984) . 5-HT receptors are present in the choroid plexus, and it has been shown that the 5-HT,, receptor that is expressed in high density in epithelial cells (Pazos et al., 1985; Yagaloff and Hartig, 1985; Nicklaus et al., 1988) is linked to mechanisms stimulating phosphotidylinositol hydrolysis and not adenylyl cyclase (Conn et al., 1986 ; for review, see Curzon and Kennett, 1990 ; but see Rudman et al., 1977; Crook et al., 1984; present results) . In broken cell preparations, we have observed that 5-HT also causes a small stimulation (V,,,,. = 29%; K, = 0.1 PM) of choroid plexus guanylyl cyclase. Whether 5-HT affects DARPP-32 and I, phosphorylation as a consequence ofguanylyl cyclase activation or as a result of phosphotidylinositol hydrolysis will require further study.
The rate of CSF secretion from choroid plexus is decreased by intravenous injection of timolol and by intraventricular injection of 5-HT and norepinephrine, the latter effect being blocked by intraventricular propranolol (Epstein et al., 1977; Feldman et al., 1979; Lindvall et al., 1979; Vogh and Godman, 1982, 1984) . These observations suggest that CAMP-dependent mechanisms may decrease CSF secretion from the choroid plexus although intracerebroventricular injection ofcholera toxin stimulated CSF production (see Epstein et al., 1977 ; for discussion, see Nathanson, 1982) . Norepinephrine-and VIP-containing fibers terminate in proximity to the choroid secretory epithelium, and sympathetic stimulation or denervation alters the rate of CSF production (Lindvall et al., 1978; Lindvall and Owman, 1981) . Likewise, in the ocular ciliary process, where DARPP-32 is also found (Stone et al., 1986 ) VIP, forskolin, cholera toxin, and &adrenergic agonists all regulate CAMP levels and decrease aqueous humor secretion (Gregory et al., 1981; Nathanson, 198 1; Caprioli et al., 1984; Mittag et al., 1985; Nilsson et al., 1986; Stone et al., 1986; reviewed in Nathanson, 1985) .
CAMP-independent mechanisms also appear to be involved in regulating CSF production in the choroid plexus. For instance, ANF decreases CSF production in the brain as well as aqueous humor secretion in the eye (Mittag et al., 1987; Steardo and Nathanson, 1987; Nathanson, 1988; Korenfeld and Becker, 1989) . Conversely, focal increases in intracranial pressure cause an increase in circulating ANF (which has potential access to choroid epithehum through fenestrated choroidal capillaries) (J. A. Nathanson and T. Miller, unpublished observations) . The effects of ANF on fluid secretion are associated with the ability of this peptide to increase cellular levels of cGMP (Hamet et al., 1984; Waldman et al., 1984) and, in the eye, are mimicked by local application of direct activators ofguanylyl cyclase such as nitroglycerin (Nathanson, 1988) .
It remains to be established what role the regulation of DARPP-32 and I, phosphorylation plays in the function of the choroid plexus. However, it is quite interesting that DARPP-32 has been localized to non-neural epithelial cells in other tissues that, like choroid plexus, are involved in fluid formation and transport, including those in the rabbit ciliary processes (Stone et al., 1986) and in the renal tubule cells of rat and monkey (Meister et al., 1989) . It is intriguing that ANF-activated guanylyl cyclase and ANFregulation offluid secretion also occur in all these epithelia. It is striking that several pathways that decrease CSF secretion (e.g., epinephrine, ANF, 5-HT), but use different second messenger systems, all enhance DARPP-32 and I, phosphorylation. Since these two proteins, when phosphorylated, are potent inhibitors of protein phosphatase-1, our observations suggest that inhibition of phosphatase-1 may be part of a final common pathway involved in the control of fluid secretion. It is therefore of particular interest that a phosphopeptide derived from DARPP-32, which inhibits phosphatase-1, was able to mimic dopamine-induced inhibition of Na,K-ATPase in the renal tubules of the thick ascending limb of the loop of Henle . It was also shown that CAMP-dependent protein kinase and protein kinase C each phosphorylate Na,K-ATPase, and that the phosphorylation is correlated with inhibition of enzyme activity (Bertorello et al., 199 1) . Since Na,K-ATPase, DARPP-32, and I, are all colocalized in choroid plexus epitheha1 cells, it is tempting to speculate that inhibition of Na,KATPase may be involved in the neural and hormonal inhibition of CSF production. Further studies of DARPP-32 and I, regulation in choroid plexus and in other secretory epithelia may provide important insights on the functions of these phosphoproteins.
